Annual report pursuant to Section 13 and 15(d)

Consolidated Financial Statements Details (Tables)

v3.22.4
Consolidated Financial Statements Details (Tables)
12 Months Ended
Dec. 31, 2022
Consolidated Financial Statements Detail  
Schedule of cost, accumulated amortization, and net carrying value of intangible assets

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of December 31, 2022

Ebopiprant IP (Note 4)

$

15,247

$

97

$

15,150

Total intangible assets

$

15,247

$

97

$

15,150

Schedule of projected amortization expense for next five years The following table presents the projected amortization expense for the next five years (in thousands):

Intangible Asset

    

Amortization

 

2023

$

897

2024

 

897

2025

 

897

2026

897

2027

897

Total

$

4,485

Schedule of accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

December 31, 

December 31, 

    

2022

    

2021

Accrued payroll and benefits

 

1,449

 

135

Accrued legal and accounting fees

867

295

Accrued incentive compensation

562

55

Other accrued liabilities

40

40

Total

$

2,918

$

525

Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders

The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2022

    

2021

Numerator

 

  

 

  

Net (loss) income

$

(17,104)

$

15,798

Less: Series A accumulated dividends

 

(2,122)

 

(2,122)

Less: Series B accumulated dividends

(3,350)

(2,438)

Less: Allocation of undistributed earnings to participating securities

 

(3,451)

Net (loss) income (attributable to) available to common stockholders, basic

$

(22,576)

$

7,787

Add: Adjustments to undistributed earnings allocated to participating securities

 

181

Net (loss) income (attributable to) available to common stockholders, diluted

$

(22,576)

$

7,968

 

Denominator

 

 

Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders

 

11,413

 

11,288

Effect of dilutive stock options

 

900

Effect of dilutive warrants

 

4

Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders

 

11,413

 

12,192

Basic net (loss) income per share (attributable to) available to common stockholders

$

(1.98)

$

0.69

Diluted net (loss) income per share (attributable to) available to common stockholders

$

(1.98)

$

0.65

Schedule of outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):

Year Ended December 31, 

    

2022

    

2021

Convertible preferred stock

5,003

Common stock options

 

885

479

Warrants for common stock

 

6

Total

 

5,894

 

479